Can you take Beqvez with Pivekimab sunirine?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- Beqvez (fidanacogene elaparvovec)
- pivekimab sunirine
Drug interactions
Moderate drug interactions
Moderate:
fidanacogene elaparvovec pivekimab sunirine
Applies to: Beqvez (fidanacogene elaparvovec) and pivekimab sunirine
Fidanacogene elaparvovec can cause liver problems, which may make the medication less effective in treating your condition. Using other medications that can also affect the liver such as pivekimab sunirine after receiving fidanacogene elaparvovec may increase that risk. Symptoms of liver problems include fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes. Blood tests to monitor liver function should be performed before and after treatment with fidanacogene elaparvovec. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
fidanacogene elaparvovec Food/Lifestyle
Applies to: Beqvez (fidanacogene elaparvovec)
After receiving fidanacogene elaparvovec, alcohol consumption should be limited for at least 1 year. Fidanacogene elaparvovec can cause liver problems, which may make the medication less effective in treating your condition. Consuming other substances that can also affect the liver such as alcohol after receiving fidanacogene elaparvovec may increase that risk. Symptoms of liver problems include fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes. Blood tests to monitor liver function should be performed before and after treatment with fidanacogene elaparvovec. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
7 potential interactions Applies to: 7 conditions, including HIV-1 Infection, Liver Disease, Alcoholism, Alcoholic Liver Damage, and Renal Dysfunction.
Alcoholic Cirrhosis
Moderate:
Beqvez
The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Alcoholic Cirrhosis.
Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.
Alcoholic Liver Damage
Moderate:
Beqvez
The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Alcoholic Liver Damage.
Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.
Alcoholism
Moderate:
Beqvez
The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Alcoholism.
Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.
HIV-1 Infection
Moderate:
Beqvez
The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with HIV-1 Infection.
There is limited information on the safety and effectiveness of fidanacogene elaparvovec in patients with HIV infection. Perform HIV testing prior to infusion, and do not administer this product to patients with either CD4+ cell count less than 200 mm3 or viral load equal to or greater than 20 copies/mL in case of serological evidence of HIV-1 or HIV-2 infection.
Infectious Hepatitis
Moderate:
Beqvez
The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Infectious Hepatitis.
Fidanacogene elaparvovec, a liver-targeting gene therapy, may carry the theoretical risk of hepatocellular carcinoma development. Patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) should be monitored with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following treatment.
Liver Disease
Moderate:
Beqvez
The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Liver Disease.
Fidanacogene elaparvovec has not been studied in patients with liver dysfunction. Furthermore, administration of this product can lead to liver transaminase elevations and hepatocyte injury. Patients should undergo a liver health assessment prior to treatment, which includes liver function tests, screening for active hepatitis B or C, and elastography and/or ultrasound to assess liver fibrosis. This product should not be administered to patients with current liver-related coagulopathy, hypoalbuminemia, persistent jaundice, or cirrhosis, portal hypertension, splenomegaly, hepatic encephalopathy, hepatic fibrosis, or active viral hepatitis.
Renal Dysfunction
Moderate:
Beqvez
The fidanacogene elaparvovec in Beqvez has a moderate potential interaction with Renal Dysfunction.
Fidanacogene elaparvovec has not been studied in patients with renal dysfunction.
Report options
More resources
Beqvez
A total of 312 drugs are known to interact with Beqvez.
- Beqvez is in the drug class miscellaneous coagulation modifiers.
- Beqvez is used to treat Hemophilia B.
pivekimab sunirine
A total of 90 drugs are known to interact with pivekimab sunirine.
- Pivekimab sunirine is in the drug class miscellaneous antineoplastics.
- Pivekimab sunirine is used to treat Blastic Plasmacytoid Dendritic Cell Neoplasm.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.